NCT01244230 - Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Atopic Dermatitis (AD) | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

July 31, 2011

Study Completion Date

August 31, 2011

Conditions

Atopic Dermatitis

Interventions

DRUG

fexofenadine/Allegra (M016455)

"Pharmaceutical form:dry syrup formulation to be suspended in water~Route of administration: oral"

Trial Locations (13)

Investigational Site Number 392012, Hitachi-Naka

Investigational Site Number 392001, Isumi

Investigational Site Number 392010, Itoshima-Shi

Investigational Site Number 392002, Katsushika-ku

Investigational Site Number 392006, Kofu

Investigational Site Number 392011, Komae-Shi

Investigational Site Number 392007, Komatsu-Shi

Investigational Site Number 392003, Kōtoku

Investigational Site Number 392013, Nagano

Investigational Site Number 392009, Okayama

Investigational Site Number 392008, Osaka

Investigational Site Number 392004, Setagaya-Ku

Investigational Site Number 392005, Setagaya-Ku